Latest Information Update: 15 Oct 2002
At a glance
- Originator Solvay
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 15 Oct 2002 Discontinued - Preclinical for Schizophrenia in Netherlands (unspecified route)
- 08 Dec 2000 New profile
- 08 Dec 2000 Preclinical development for Schizophrenia in Netherlands (Unknown route)